Universal International Scientific Journal
5
9
Pirmatov Shakhbozbek Shukhratbek ugli
Assistant of Department of Epidemiology and Infectious Diseases
FMIOPH
Uzbekistan
https://orcid.org/0009-0005-5336-6668
Abstract:
The urogenital form of diabetic autonomic neuropathy (DAN) is a common yet
underdiagnosed complication of diabetes, severely affecting quality of life. This review covers clinical
manifestations like bladder and erectile dysfunction, diagnostic methods, and treatments, including
glycemic control, PDE5 inhibitors, neuromodulation, and emerging therapies. Persistent challenges
highlight the need for multidisciplinary approaches and further research into personalized strategies.
Keywords:
diabetic autonomic neuropathy (DAN), urogenital dysfunction, bladder dysfunction,
erectile dysfunction, neurophysiological diagnostics, multidisciplinary treatment.
Annotatsiya:
Diabetik vegetativ neyropatiyaning (DVN) urogenital shakli diabetning keng
tarqalgan, ammo tashxislanmagan asorati bo‘lib, hayot sifatiga jiddiy ta’sir qiladi. Ushbu sharhda siydik
pufagi va erektil disfunksiyasi, diagnostika usullari va davolash usullari, jumladan glikemik nazorat, PDE5
ingibitorlari, neyromodulyatsiya va rivojlanayotgan terapiya kabi klinik ko‘rinishlar yoritilgan. Doimiy
Universal Xalqaro Ilmiy Jurnal
Jurnalning bosh sahifasi:
CLINICAL FEATURES AND TREATMENT OF UROGENITAL DIABETIC AUTONOMIC
NEUROPATHY
Universal International Scientific
Year: 2025 Issue: 2 Volume: 1
Published: 08.01.2025
International indexes
Universal International Scientific Journal
6
0
muammolar ko‘p tarmoqli yondashuvlar va shaxsiylashtirilgan strategiyalarni yanada tadqiq qilish
zarurligini ta’kidlaydi.
Kalit so‘zlar:
diabetik vegetativ neyropatiya (DAN), urogenital disfunksiya, siydik pufagi
disfunksiyasi, erektil disfunksiya, neyrofiziologik diagnostika, ko‘p tarmoqli davolash.
Аннотация:
Урогенитальная форма диабетической вегетопатии (ДВН) является
распространенным, но недостаточно диагностируемым осложнением диабета, серьезно влияющим
на качество жизни. Этот обзор охватывает такие клинические проявления, как дисфункция
мочевого пузыря и эрекции, методы диагностики и лечения, включая контроль гликемии,
ингибиторы PDE5, нейромодуляцию и новую терапию. Постоянные вызовы подчеркивают
необходимость
многодисциплинарных
подходов
и
дальнейших
исследований
персонализированных стратегий.
Ключевые слова:
диабетическая вегетативная нейропатия (ДВН), урогенитальная
дисфункция, дисфункция мочевого пузыря, эректильная дисфункция, нейрофизиологическая
диагностика, многопрофильное лечение.
Language:
English
Citation:
Pirmatov , S. (2025). CLINICAL FEATURES AND TREATMENT OF UROGENITAL
DIABETIC AUTONOMIC NEUROPATHY. Universal International Scientific Journal, 2(1), 59–67.
https://doi.org/10.69891/3060-4540.2025.39.71.001
Doi:
https://doi.org/10.5281/zenodo.14711437
Crosreff doi:
https://doi.org/10.69891/3060-4540.2025.39.71.001
INTRODUCTION.
Diabetic autonomic polyneuropathy
(DAN) significantly impacts the urogenital
system, manifesting as diabetic bladder
dysfunction, sexual dysfunction, and
recurrent urinary tract infections, which are
more prevalent than other diabetic
complications
like
neuropathy
or
nephropathy[1]. The prevalence of these
conditions is notably high, with over 50%
of individuals with diabetes experiencing
lower urinary tract symptoms (LUTS) and
erectile dysfunction (ED), and up to 39%
of
women
suffering
from
urinary
incontinence. These dysfunctions are
linked to abnormalities in the detrusor
muscle, urothelium, and urethra, and are
influenced by neurogenic, vasculogenic,
hormonal, metabolic, drug-induced, and
psychological factors[2]. The UroEDIC
study, part of the DCCT/EDIC research,
highlighted
significant
associations
between
cardiovascular
autonomic
neuropathy and urologic complications,
underscoring the need for comprehensive
management
strategies[1,3].
Universal International Scientific Journal
61
Understanding the prevalence and quality-
of-life implications of these conditions is
crucial, as they severely affect patients'
well-being
and
are
often
underdiagnosed[4].
Effective
clinical
management requires a multidisciplinary
approach,
incorporating
lifestyle
interventions, pharmacological treatments,
and psychological counseling. Recent
advancements in antihyperglycemic drugs
also show promise in improving sexual
function
through
weight
control[2].
Despite these developments, there remains
a critical need for further research to
enhance
diagnostic
and
treatment
protocols, as well as to address the social
determinants of health that influence the
management of DAN[5].
PATHOPHYSIOLOGY AND
EPIDEMIOLOGY
.
Diabetic
autonomic
neuropathy
(DAN) is a prevalent complication of
diabetes
mellitus,
affecting
multiple
systems, including the urogenital system,
which leads to significant morbidity. The
mechanisms of autonomic nerve damage in
diabetes
involve
microvascular
complications that impair nerve function,
resulting in a range of dysfunctions across
the cardiovascular, gastrointestinal, and
urogenital systems[6,7]. In the urogenital
system, diabetic autonomic neuropathy
manifests as bladder dysfunction, sexual
dysfunction, and recurrent urinary tract
infections, with both men and women
experiencing these complications[1,6]. The
pathways specifically affected include
those responsible for erectile function in
men and sexual function in women, as well
as lower urinary tract symptoms[1]. The
prevalence
of
urogenital
diabetic
neuropathy is notably high, with studies
such as the UroEDIC study highlighting
significant
associations
between
cardiovascular autonomic neuropathy and
urologic complications in individuals with
type 1 diabetes[1,3]. Risk factors for
developing these complications include
poor glycemic control, longer duration of
diabetes, and associated cardiovascular
risk
factors.
Demographically,
the
prevalence and incidence of autonomic
neuropathy,
including
urogenital
manifestations, vary widely due to
differences in study populations and
diagnostic criteria, but it is clear that these
complications are more common in
individuals with prolonged diabetes[8].
Understanding these mechanisms and
epidemiological factors is crucial for
developing effective management and
prevention
strategies
for
urogenital
diabetic neuropathy.
CLINICAL NEUROLOGICAL
FEATURES.
Diabetic
autonomic
neuropathy
(DAN) significantly impacts the urogenital
system, manifesting primarily as bladder
and sexual dysfunction. Key symptoms of
urogenital
dysfunction
in
diabetic
autonomic neuropathy include lower
urinary tract symptoms (LUTS) such as an
overactive or poorly contractile bladder,
erectile dysfunction (ED) in men, and
Universal International Scientific Journal
6
2
changes in sexual activity and function in
women. These symptoms are prevalent,
with over 50% of diabetic patients
experiencing LUTS and ED, and urinary
incontinence affecting up to 39% of
women with diabetes[1,2]. The assessment
of neurological damage in diabetic patients
involves a comprehensive clinical history
and physical examination, focusing on
autonomic symptoms. Diagnostic tools
include questionnaires, bladder diaries,
urinalysis, uroflowmetry, and urodynamics
for LUTS, while ED evaluation involves
medical and sexual history, psychological
evaluation, hormone level testing, and
cardiovascular
autonomic
function
tests[2,4,9]. Differential diagnoses for
urogenital dysfunction in diabetes should
consider other potential causes such as
neurogenic,
vasculogenic,
hormonal,
metabolic,
drug-induced,
and
psychological
factors.
Additionally,
conditions
like
amyloidosis,
uremic
neuropathy, vitamin B12 deficiency,
paraneoplastic autonomic neuropathy, HIV
infection, and alcoholic neuropathy should
be considered, as they can present with
similar autonomic symptoms[10,11]. The
UroEDIC study highlights the significant
association
between
cardiovascular
autonomic neuropathy and urogenital
complications, emphasizing the need for a
multidisciplinary approach to diagnosis
and
management[3].
Effective
management of these dysfunctions often
requires a combination of pharmacological
treatments, lifestyle interventions, and
psychological counseling, tailored to the
specific
symptoms
and
underlying
causes[2,6].
NEUROPHYSIOLOGICAL
CHARACTERISTICS.
Urodynamic
studies,
nerve
conduction studies, evoked potential
testing, and emerging neurophysiological
markers are critical tools in assessing
autonomic dysfunction in the urogenital
form of diabetic neuropathy. Urodynamic
studies are considered the gold standard for
evaluating lower urinary tract function in
neuro-urological patients, including those
with diabetic neuropathy. These studies
help identify conditions such as neurogenic
detrusor
overactivity
and
detrusor-
sphincter dyssynergia, which are crucial
for risk stratification and management of
urological comorbidities[12,13]. Nerve
conduction studies, although limited in
diagnosing small-fiber neuropathy, are
useful in detecting abnormalities in motor
and sensory nerve functions, which can be
indicative of diabetic neuropathy[14,15].
Evoked
potential
testing,
such
as
somatosensory-evoked potentials (SSEP)
and sympathetic skin response (SSR),
provides non-invasive means to detect
early urinary and sexual dysfunction in
diabetic patients, offering a significant
advantage
in
early
diagnosis[14].
Emerging neurophysiological markers,
including cutaneous silent periods (CSPs),
have shown promise in diagnosing small-
fiber neuropathy, with CSPs demonstrating
higher diagnostic utility than traditional
Universal International Scientific Journal
6
3
autonomic tests[15]. However, these
diagnostic methods have limitations.
Urodynamic studies, while comprehensive,
are invasive and may not be suitable for all
patients[12]. Nerve conduction studies
often fail to detect small-fiber neuropathy,
which is a common issue in diabetic
patients[15].
Evoked
potential
tests,
although non-invasive, may not always
correlate with clinical symptoms, leading
to potential underdiagnoses[14]. Despite
these limitations, these diagnostic tools,
when used in conjunction, provide a robust
framework
for
assessing
autonomic
dysfunction
in
diabetic
neuropathy,
guiding
therapeutic
decisions
and
improving patient outcomes[16,17].
TREATMENT METHODS.
The treatment of the urogenital form
of diabetic autonomic neuropathy (DAN)
involves a multifaceted approach that
includes both pharmacological and non-
pharmacological
strategies.
Pharmacologically, glycemic control is
paramount as it can mitigate the severity of
autonomic
neuropathy
and
its
complications, including those affecting
the
urogenital
system[18,19].
Phosphodiesterase
type
5
(PDE5)
inhibitors are the first-line treatment for
erectile dysfunction (ED) in men, a
common manifestation of urogenital
DAN[20,21]. For bladder dysfunction,
antimuscarinics or β-3 agonists are
recommended for detrusor overactivity,
while intermittent catheterization and
neuromodulation are used for underactive
bladder[22].
Non-pharmacological
strategies include lifestyle modifications
such as diet and exercise, which are crucial
for glycemic control and overall health
improvement[19,23]. Physical therapy and
neuromodulation techniques, such as tibial
nerve
stimulation
and
sacral
neuromodulation,
are
employed
for
bladder
dysfunction[22].
Emerging
therapies are being explored, including
stem cell treatments and advanced
glycation end-product inhibitors, although
these are still in the experimental stages
and not yet widely implemented[19]. The
management of female sexual dysfunction,
often driven by social and psychological
factors,
requires
a
multidisciplinary
approach, including lifestyle interventions
and hormone therapy in postmenopausal
women[22]. Despite the availability of
these
treatments,
there
remains
a
significant gap in effective management
due to underdiagnosis and limited clinical
research, highlighting the need for a
comprehensive
and
multidisciplinary
approach to improve outcomes for patients
with
diabetic
urogenital
dysfunction[22,24].
CHALLENGES AND FUTURE
DIRECTIONS.
Urogenital
diabetic
autonomic
neuropathy (DAN) presents significant
unmet needs in both clinical management
and research, primarily due to its complex
pathophysiology
and
the
challenges
associated with early detection. The
condition affects the urogenital system,
Universal International Scientific Journal
64
leading to bladder and sexual dysfunction,
which significantly impacts the quality of
life for individuals with diabetes[25,26].
Despite its prevalence, there is a
widespread
underdiagnosis
of
these
dysfunctions, partly due to limited clinical
research and knowledge, which hinders
effective
management[25,27].
Early
detection of diabetic neuropathy, including
urogenital
manifestations,
remains
challenging due to the often asymptomatic
nature of the condition in its initial
stages[28,29]. The lack of reliable
biomarkers for early neuropathic changes
further complicates timely diagnosis and
intervention[29]. Current management
strategies for urogenital dysfunctions, such
as erectile dysfunction and bladder issues,
involve a combination of pharmacological
treatments, lifestyle interventions, and
psychological counseling, yet these are
often only partially effective and can be
associated with adverse effects[25,26].
Advances in personalized medicine hold
promise for addressing these challenges by
tailoring treatments to individual patient
profiles, potentially improving outcomes.
However, the development of such
personalized approaches requires a deeper
understanding of the genetic, metabolic,
and environmental factors contributing to
DAN[30,31]. Future therapies may benefit
from integrating novel glucose-lowering
agents, which have shown potential in
reducing cardiovascular events and may
indirectly
benefit
autonomic
neuropathy[30]. Additionally, the use of
wearable devices and innovative screening
methods could enhance early detection and
monitoring, although further research is
needed
to
optimize
these
technologies[30,32]. Overall, addressing
the unmet needs in urogenital diabetic
autonomic
neuropathy
requires
a
multidisciplinary
approach,
increased
awareness, and continued research into
effective
diagnostic
and
therapeutic
strategies[25,33]. The management of
urogenital diabetic autonomic neuropathy
(DAN) presents several challenges. Early
detection remains difficult due to the
asymptomatic nature of initial stages and a
lack
of
reliable
biomarkers.
Most
diagnostic techniques, such as urodynamic
studies and nerve conduction tests, focus
on advanced stages of dysfunction, leaving
early
interventions
limited.
[34,35].
Additionally, underreporting of symptoms
by patients, often due to social stigma or
lack
of
awareness,
contributes
to
underdiagnosis and delayed treatment.
Current
treatment
strategies,
while
effective in symptom management, often
fail to address the progressive nature of
autonomic
neuropathy[36,37]..
Pharmacological approaches, such as
PDE5 inhibitors for erectile dysfunction or
antimuscarinics for bladder dysfunction,
primarily target symptoms rather than
underlying nerve damage. Similarly, non-
pharmacological
methods
like
neuromodulation
and
lifestyle
interventions, while promising, require
further research to optimize protocols and
Universal International Scientific Journal
6
5
enhance accessibility[38,39].. Advances in
personalized medicine offer hope for
tailored treatment options that consider
genetic, metabolic, and environmental
factors. Innovative therapies, including
stem cell applications and advanced
glycation end-product inhibitors, show
potential but are still in experimental
stages. Integrating these approaches with
modern screening technologies, such as
wearable
devices
for
continuous
monitoring, could significantly improve
early detection and long-term outcomes.
Despite these advancements, gaps in
research and clinical practice persist,
particularly in addressing the psychosocial
aspects
of
urogenital
dysfunction.
Comprehensive, multidisciplinary care
involving endocrinologists, urologists,
neurologists,
and
mental
health
professionals is essential to tackle the
multifaceted impact of urogenital DAN
and improve patient outcomes[40].
CONCLUSION.
Urogenital diabetic autonomic
neuropathy is a significant complication of
diabetes that profoundly affects patient
well-being.
Early
diagnosis
using
advanced neurophysiological tools and a
combination of pharmacological and non-
pharmacological treatments are essential
for effective management. However,
persistent challenges in detection and
therapy highlight the need for greater
awareness, multidisciplinary strategies,
and continued research into innovative
treatment modalities.
REFERENCES:
1.
Nnenaya Agochukwu-Mmonu et al. Autonomic neuropathy and urologic complications in
diabetes. // Autonomic Neuroscience: Basic and Clinical. 2020. Vol. 229. P. 102736–102736.
2.
Maria Raineri. Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in
Diabetes. 2023. P. 491–529.
3.
Barbara H. Braffett, Hunter Wessells, Aruna V. Sarma. Urogenital Autonomic Dysfunction
in Diabetes // Current Diabetes Reports. 2016. Vol. 16, № 12. P. 119–119.
4.
Aaron I. Vinik et al. Neurological Disease and Diabetes, Autonomic. 2004. P. 334–339.
5.
Rodica Pop-Busui. Autonomic diabetic neuropathies: A brief overview. // Diabetes
Research and Clinical Practice. 2023. Vol. 206 Suppl 1. P. 110762–110762.
6.
Anastasios Tentolouris, Nikolaos Tentolouris. Diabetic Autonomic Neuropathy. 2021. P.
307–315.
7.
Roy Freeman. Diabetic autonomic neuropathy. // Handbook of Clinical Neurology. 2014.
Vol. 126. P. 63–79.
8.
Rodica Pop-Busui, Andrew J.M. Boulton, Jay M. Sosenko. Peripheral and Autonomic
Neuropathy in Diabetes. 2018.
9.
Chong Hwa Kim. Diagnosis and Management of Diabetic Autonomic Neuropathy // The
Journal of Korean Diabetes. 2018. Vol. 19, № 3. P. 160–167.
10.
Juan Idiaquez, Eduardo E. Benarroch, Martin Nogues. Autonomic Failure in Chronic
Peripheral Neuropathy. 2018. P. 73–86.
11.
Takashi Ito et al. Urinary dysfunction and autonomic control in amyloid neuropathy //
Clinical Autonomic Research. 2006. Vol. 16, № 1. P. 66–71.
12.
Andry Perrin, Jacques Corcos. The Utility of Urodynamic Studies in Neuro-Urological
Patients // Advances in Cardiovascular Diseases. 2023. Vol. 11, № 4. P. 1134–1134.
Universal International Scientific Journal
66
13.
Hazel Ecclestone, Rizwan Hamid. Clinical Neuro-urophysiological Investigations. 2018. P.
181–189.
14.
Hanan El Sebaie El Hefnawy et al. Evaluation of different electrophysiological studies in
the detection of urinary and sexual dysfunction in diabetic women // Egyptian Rheumatology and
Rehabilitation. 2013. Vol. 40, № 1. P. 39–49.
15.
Pinar Kahraman Koytak et al. Assessment of symptomatic diabetic patients with normal
nerve conduction studies: utility of cutaneous silent periods and autonomic tests. // Muscle & Nerve.
2011. Vol. 43, № 3. P. 317–323.
16.
Guillaume Lamotte, Paola Sandroni. Updates on the Diagnosis and Treatment of
Peripheral Autonomic Neuropathies // Current Neurology and Neuroscience Reports. 2022. Vol. 22, №
12. P. 823–837.
17.
Charushila Atul Rukadikar, Atul R. Rukadikar, Surekha Kishore. A Review on Autonomic
Functional Assessment in Diabetic Patients // Cureus. 2023. Vol. 15, № 2. P. e34598–e34598.
18.
David S.H. Bell. Detecting and treating the protean manifestations of diabetic autonomic
neuropathy // Diabetes, Obesity and Metabolism. 2023. Vol. 25. P. 1162–1173.
19.
Strategies for the prevention or reversal of neuropathy. 2022. P. 259–281.
20.
Anastasios Tentolouris, Nikolaos Tentolouris. Diabetic Autonomic Neuropathy. 2021. P.
307–315.
21.
Dan Ziegler. Autonome diabetische Neuropathie // Diabetologe. 2020. Vol. 16, № 3. P.
315–326.
22.
Maria Raineri. Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in
Diabetes. 2023. P. 491–529.
23.
Alaka Deshpande. Diabetic Autonomic Neuropathy // Journal of the Medical Sciences.
2018. Vol. 5, № 2. P. 85–87.
24.
Nnenaya Agochukwu-Mmonu et al. Autonomic neuropathy and urologic complications in
diabetes. // Autonomic Neuroscience: Basic and Clinical. 2020. Vol. 229. P. 102736–102736.
25.
Maria Raineri. Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in
Diabetes. 2023. P. 491–529.
26.
Anastasios Tentolouris, Nikolaos Tentolouris. Diabetic Autonomic Neuropathy. 2021. P.
307–315.
27.
Ogli N.A.K., Qahhorali G. IMPROVEMENT OF SURGICAL TACTICS AND
TREATMENT OF COMBINED INJURIES IN CHILDREN: 5–2 // Eurasian Journal of Medical and
Natural Sciences. Республика Узбекистан, Ташкент: ООО «Innovative Academy RSC», 2024. Vol. 4,
№ 5–2. P. 17–21.
28.
Advances in screening, early diagnosis, and accurate staging of diabetic neuropathy. 2022.
P. 47–78.
29.
Josie Carmichael et al. Advances in Screening, Early Diagnosis and Accurate Staging of
Diabetic Neuropathy. // Frontiers in Endocrinology. 2021. Vol. 12. P. 671257–671257.
30.
Aikaterini Eleftheriadou et al. Cardiovascular autonomic neuropathy in diabetes: an update
with a focus on management // Diabetologia. 2024.
31.
Lynn Ang et al. The conundrum of diabetic neuropathies-Past, present, and future. //
Journal of Diabetes and Its Complications. 2022. Vol. 36 11, № 11. P. 108334–108334.
32.
Salem Beshyah et al. Current Perspectives in Pre- and Diabetic Peripheral Neuropathy
Diagnosis and Management: An Expert Statement for the Gulf Region // Diabetes Therapy. 2024.
33.
Prawej Ansari et al. Challenges in Diabetic Micro-Complication Management: Focus on
Diabetic Neuropathy // International Journal of Technology Management. 2021. Vol. 1, № 3. P. 175–186.
34.
Shuxrat o‘g‘li P. S. EEG CHARACTERISTICS OF DIFFERENT TYPES OF FOCAL
EPILEPSY IN ADULT PATIENTS //Web of Medicine: Journal of Medicine, Practice and Nursing. –
2023. – Т. 1. – №. 9. – С. 1-3.
Universal International Scientific Journal
67
35.
Жураев, С. Б. ОПТИМИЗАЦИЯ ТАКТИКИ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ
ПОВРЕЖДЕНИЙ АРТЕРИЙ КОНЕЧНОСТЕЙ ПРИ СОЧЕТАННЫХ ТРАВМАХ. «YOSH
OLIMLAR TIBBIYOT JURNALI» TASHKENT MEDICAL ACADEMY «MEDICAL JOURNAL OF
YOUNG SCIENTISTS» ТАШКЕНТСКАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ, 82.
36.
Jurayev S.B. (2024). CURRENT TREATMENT OPTIONS OF ADHESIVE SMALL
BOWEL OBSTRUCTION (LITERATURE REVIEW). https://doi.org/10.5281/zenodo.14506496
37.
Abdurakhmonov, N. (2024). THE IMPORTANCE OF DIFFERENTIAL DIAGNOSING
IN TREATMENT OF MARGINAL BLEPHARITIS WITH DEMODEX ETIOLOGY. Science and
innovation, 3(D5), 188-192.
38.
O’Gli P. S. S. KATTA YOSHLI BEMORLARDA FOKAL EPILEPSIYANI TURLI
XILLIGINI EEG XUSUSIYATLARI //Ta’lim fidoyilari. – 2022. – Т. 5. – №. 9. – С. 621-624.
39.
Niyozbek Abdurakhmonov Khamdamjon Ogli, & Gulomov Qahhorali (2024).
IMPROVEMENT OF SURGICAL TACTICS AND TREATMENT OF COMBINED INJURIES IN
CHILDREN. Eurasian Journal of Medical and Natural Sciences, 4 (5-2), 17-21. doi:
10.5281/zenodo.11367251
40.
Пирматов Ш.Ш., Рахматуллаева Н.И., & Холматов Р.И. (2021). ОСОБЕННОСТИ
ЭЭГ РАЗЛИЧНЫХ ТИПОВ ФОКАЛЬНОЙ ЭПИЛЕПСИИ У ВЗРОСЛЫХ ПАЦИЕНТОВ.
Экономика и социум, (10 (89)), 964-971.
